evidence card · glp1_broad_health_benefit
GLP-1 receptor agonists (semaglutide, tirzepatide) deliver large health benefits for people with obesity/T2D
H5
▲ supports
stakes high
11 posts scored
·
across 8 accounts
·
2 sources
Summary
SELECT (NEJM 2023) showed CV event reduction with semaglutide in overweight/obese non-diabetics with prior CVD. Weight loss and glycemic benefits are consistent across trials. 'Elixir' language overstates the clinical scope.
Five-score assessment
Scores not yet assigned for this card. (Legacy card; will be populated on next refinement.)
Scope
Population
adults with obesity or T2D
Intervention
GLP-1 RAs (semaglutide, tirzepatide)
Outcome
weight, glycemia, CV events (SELECT)
Not supported for
- universal 'elixir' claim for healthy-weight individuals
- long-term maintenance without adherence